Actively Recruiting
Implementation of HPV Testing in Patients After Radiotherapy for Cervical Cancer
Led by General University Hospital, Prague · Updated on 2026-03-25
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of HPV testing to monitor patients who have undergone chemoradiotherapy (CRT) for cervical cancer. This observational trial focuses on women with cervical cancer stages IB to IVA who received primary radiotherapy aimed at curing the disease. The study seeks to understand how well HPV-based molecular tests can detect cancer recurrence compared to current methods like clinical exams and imaging. The study will collect samples before treatment and during follow-up visits at 3, 12, and 24 months after CRT completion. HPV detection will be done using two methods: PCR testing of HPV DNA from cervical swabs and analysis of circulating HPV DNA fragments in blood. These approaches aim to track HPV clearance and recurrence sensitivity over a two-year period. Participants will undergo sample collection and monitoring visits during the two years following treatment. Researchers will assess how accurately HPV DNA testing detects cancer recurrence and compare the effectiveness of cervical swabs versus blood tests. The study will also look at HPV types present before and after treatment and evaluate treatment outcomes for patients with detected recurrence.
CONDITIONS
Brief Title
HPV After chemoRadioTherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient indicated for primary radiotherapy for cervical cancer
- Cervical cancer stage IB to IVA
- Signed informed consent
- Age 18 years or older
- Radiotherapy administered with curative intent
You will not qualify if you...
- Cervical cancer stage IA
- Cervical cancer stage IVB
- Previous radiotherapy in the pelvic area
- Hysterectomy performed before starting radiotherapy
- History of HPV-associated cancer
- HIV infection or other significant immunodeficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 years
Participants who have completed primary (chemo)radiotherapy for cervical cancer are observed for HPV recurrence using cervical swabs and blood tests.
Regular visits during the 2-year observation period as per study schedule
Trial Site Locations
Total: 1 location
1
General Faculty Hospital in Prague
Prague, Czechia, 12800
Actively Recruiting
Research Team
L
Lukas Dostalek, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here